Stock Events

Senseonics 

$0.48
330
+$0.01+1.87% Friday 20:00

Statistics

Day High
0.49
Day Low
0.47
52W High
1.05
52W Low
0.37
Volume
1,679,424
Avg. Volume
2,349,461
Mkt Cap
252.17M
P/E Ratio
-3.46
Dividend Yield
-
Dividend
-

Earnings

13MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.13
-0.08
-0.03
0.02
Expected EPS
-0.03
Actual EPS
-0.03

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SENS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap45.36B
Dexcom produces continuous glucose monitoring systems for diabetes management, directly competing with Senseonics' Eversense CGM system.
Abbott Laboratories
ABT
Mkt Cap181.3B
Abbott Laboratories offers the FreeStyle Libre, a flash glucose monitoring system, competing in the glucose monitoring space.
Tandem Diabetes Care
TNDM
Mkt Cap2.61B
Tandem Diabetes Care manufactures insulin pumps and integrated diabetes management systems, competing in the broader diabetes management market.
Insulet
PODD
Mkt Cap13.79B
Insulet Corporation develops the Omnipod, an insulin management system, which competes with diabetes management solutions like Senseonics'.
Medtronic
MDT
Mkt Cap99.95B
Medtronic offers the Guardian Sensor 3 CGM and insulin pumps, providing integrated diabetes management solutions.
Mirum Pharmaceuticals
MIRM
Mkt Cap1.62B
Mirum Pharmaceuticals, though more focused on liver diseases, has interests in metabolic disorders, potentially overlapping with diabetes management.
Novo Nordisk
NVO
Mkt Cap481.67B
Novo Nordisk specializes in diabetes care with insulin and GLP-1 receptor agonists, indirectly competing in diabetes management.
Sanofi
SNY
Mkt Cap130B
Sanofi produces insulin and other diabetes medications, competing in the broader market for diabetes management.
Merck &
MRK
Mkt Cap323.59B
Merck & Co., with its diabetes medication portfolio, including Glucophage, competes in the pharmaceutical management of diabetes.
Bristol-Myers Squibb
BMY
Mkt Cap82.02B
Bristol-Myers Squibb, through its metabolic disorders treatment portfolio, indirectly competes in the diabetes management space.

Analyst Ratings

2$Average Price Target
The highest estimate is $2.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Electronic Technology
Electronic Components
Manufacturing
Surgical and Medical Instrument Manufacturing
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Show more...
CEO
Timothy Goodnow
Employees
132
Country
US
ISIN
US81727U1051
WKN
000A2AGQW

Listings